MA50254A - Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido - Google Patents

Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido

Info

Publication number
MA50254A
MA50254A MA050254A MA50254A MA50254A MA 50254 A MA50254 A MA 50254A MA 050254 A MA050254 A MA 050254A MA 50254 A MA50254 A MA 50254A MA 50254 A MA50254 A MA 50254A
Authority
MA
Morocco
Prior art keywords
ido
prophylactic
expression
therapeutic agent
diseases involving
Prior art date
Application number
MA050254A
Other languages
English (en)
Inventor
Hiromi Muraoka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA50254A publication Critical patent/MA50254A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050254A 2017-09-15 2018-09-14 Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido MA50254A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017178247 2017-09-15

Publications (1)

Publication Number Publication Date
MA50254A true MA50254A (fr) 2020-07-22

Family

ID=65723397

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050254A MA50254A (fr) 2017-09-15 2018-09-14 Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido

Country Status (15)

Country Link
US (1) US20200281904A1 (fr)
EP (1) EP3682900A4 (fr)
JP (1) JP6931067B2 (fr)
KR (1) KR102403289B1 (fr)
CN (1) CN111107876A (fr)
AU (1) AU2018333751B2 (fr)
BR (1) BR112020005100A2 (fr)
CA (1) CA3075870A1 (fr)
MA (1) MA50254A (fr)
MX (1) MX2020002886A (fr)
PH (1) PH12020500510A1 (fr)
RU (1) RU2020113456A (fr)
SG (1) SG11202002316PA (fr)
TW (1) TWI733055B (fr)
WO (1) WO2019054465A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518080B2 (ja) * 2019-08-06 2024-07-17 大鵬薬品工業株式会社 アザ二環式化合物とポリアデノシン５’二リン酸リボースポリメラーゼ阻害剤を用いたがん併用療法
AU2023282693A1 (en) 2022-06-10 2025-01-02 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition containing pimitespib
JPWO2023238930A1 (fr) 2022-06-10 2023-12-14
KR20260049608A (ko) 2023-08-24 2026-04-14 다이호야쿠힌고교 가부시키가이샤 아자 2 고리형 화합물과 항안드로겐제를 사용한 암 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321645A1 (fr) * 2008-08-18 2011-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibilité aux inhibiteurs hsp90
AU2010269674B2 (en) 2009-07-10 2014-01-16 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
PE20151593A1 (es) * 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
DK3053578T3 (da) * 2013-09-30 2021-02-01 Taiho Pharmaceutical Co Ltd Kombinationscancerterapi ved hjælp af azabicycloforbindelse
CA2985033C (fr) * 2015-05-12 2020-02-25 Taiho Pharmaceutical Co., Ltd. Sous forme cristalline ii de 3-ethyle -4-{3-isopropyl-4-(4-(1-methyle-1h-pyrazol- 4-yl)-1h-imidazole-1-yl)-1hpyrazol0[3,4-b]pyridin-1-yl} benzamide

Also Published As

Publication number Publication date
JPWO2019054465A1 (ja) 2020-08-20
WO2019054465A1 (fr) 2019-03-21
AU2018333751B2 (en) 2021-12-02
TW201919708A (zh) 2019-06-01
US20200281904A1 (en) 2020-09-10
TWI733055B (zh) 2021-07-11
KR102403289B1 (ko) 2022-05-30
MX2020002886A (es) 2020-10-01
AU2018333751A1 (en) 2020-04-02
RU2020113456A (ru) 2021-10-15
KR20200037367A (ko) 2020-04-08
RU2020113456A3 (fr) 2021-10-15
EP3682900A1 (fr) 2020-07-22
JP6931067B2 (ja) 2021-09-01
CA3075870A1 (fr) 2019-03-21
PH12020500510A1 (en) 2021-05-17
CN111107876A (zh) 2020-05-05
EP3682900A4 (fr) 2021-06-16
BR112020005100A2 (pt) 2020-09-15
SG11202002316PA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
EP3370748A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP2861246A4 (fr) Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3986426A4 (fr) Ciblage de l'intégrine alpha3bêta1 pour le traitement du cancer et d'autres maladies
EP3849591A4 (fr) Méthodes et compositions pour traiter des maladies de la peau
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3741376A4 (fr) Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
SG11202002316PA (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
EP3331356A4 (fr) Fragments et dérivés de la progranuline (pgrn) pour le traitement ou le soulagement des maladies lysosomales
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
EP3597198A4 (fr) Composition pour traitement des maladies articulaires, et kit contenant cette composition
MA41142A (fr) Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse
EP3452015A4 (fr) Compositions et méthodes pour le traitement de l'inflammation ou de l'infection de l'oeil